Levamisole for chronic hepatitis B

  • Protocol
  • Intervention

Authors

  • Kate Whitfield,

    Corresponding author
    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    • Kate Whitfield, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, DK-2100, Denmark. kate.whitfield@ctu.rh.dk.

    Search for more papers by this author
  • Lina Saem Stoey,

    1. Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark
    Search for more papers by this author
  • Maria Skoog,

    1. Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark
    Search for more papers by this author
  • Jane Lindschou Hansen,

    1. Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark
    Search for more papers by this author
  • Khalid Mumtaz,

    1. Aga Khan University Hospital, Department of Medicine, Karachi, Pakistan
    Search for more papers by this author
  • Christian Gluud

    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the beneficial and harmful effects of levamisole for patients with chronic hepatitis B.